George M. Lasezkay Sells 20,030 Shares of Clearside Biomedical, Inc. (NASDAQ:CLSD) Stock

Clearside Biomedical, Inc. (NASDAQ:CLSD – Get Rating) CEO George M. Lasezkay sold 20,030 shares of Clearside Biomedical stock in a transaction on Thursday, January 19th. The stock was sold at an average price of $1.46, for a total transaction of $29,243.80. Following the completion of the sale, the chief executive officer now owns 484,577 shares of the company’s stock, valued at approximately $707,482.42. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Clearside Biomedical Stock Performance

Shares of CLSD opened at $1.50 on Monday. Clearside Biomedical, Inc. has a 1 year low of $0.98 and a 1 year high of $2.85. The company has a market cap of $90.29 million, a price-to-earnings ratio of -18.75 and a beta of 1.83. The firm has a fifty day moving average of $1.27 and a 200-day moving average of $1.35.

Clearside Biomedical (NASDAQ:CLSD – Get Rating) last announced its quarterly earnings results on Wednesday, November 9th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.17). Clearside Biomedical had a negative net margin of 17.15% and a negative return on equity of 16.13%. The firm had revenue of $0.27 million for the quarter, compared to analyst estimates of $16.50 million. Analysts predict that Clearside Biomedical, Inc. will post -0.52 EPS for the current year.

Wall Street Analysts Forecast Growth

CLSD has been the subject of a number of research analyst reports. Needham & Company LLC upgraded shares of Clearside Biomedical from a “hold” rating to a “buy” rating and set a $5.00 price target for the company in a research note on Thursday, November 10th. StockNews.com assumed coverage on shares of Clearside Biomedical in a research note on Friday, November 4th. They issued a “hold” rating for the company. HC Wainwright boosted their target price on shares of Clearside Biomedical from $5.00 to $6.00 and gave the company a “buy” rating in a research note on Thursday, November 10th. Finally, Stifel Nicolaus upgraded shares of Clearside Biomedical from a “hold” rating to a “buy” rating and set a $8.00 target price for the company in a research note on Wednesday, November 9th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, Clearside Biomedical currently has an average rating of “Moderate Buy” and an average price target of $7.60.

Hedge Funds Weigh In On Clearside Biomedical

Several hedge funds and other institutional investors have recently modified their holdings of the company. Balyasny Asset Management LLC acquired a new stake in Clearside Biomedical in the third quarter worth about $25,000. Mackenzie Financial Corp acquired a new stake in Clearside Biomedical in the first quarter worth about $27,000. JPMorgan Chase & Co. lifted its holdings in Clearside Biomedical by 100.6% in the second quarter. JPMorgan Chase & Co. now owns 18,161 shares of the company’s stock worth $27,000 after purchasing an additional 9,109 shares during the period. Newman Dignan & Sheerar Inc. acquired a new stake in Clearside Biomedical in the third quarter worth about $31,000. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Clearside Biomedical by 34.3% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 67,170 shares of the company’s stock worth $76,000 after purchasing an additional 17,141 shares during the period. Institutional investors and hedge funds own 20.07% of the company’s stock.

Clearside Biomedical Company Profile

(Get Rating)

Clearside Biomedical, Inc is a biopharmaceutical company, which delivers therapies to the back of the eye through the suprachoroidal space. Its pipeline include CLS-AX, Integrin Inhibitor, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F.